$GKOS

Navratil Tomas sold $201K of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 1,537 shares of GLAUKOS Corp (GKOS) at $130.68 ($0.20M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Navratil Tomas
Published Jun 18, 2026, 11:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The disclosed sale is a concrete, newly filed datapoint that can influence short-term sentiment, but the 10b5-1 structure generally limits inference about near-term fundamentals.

02

Market read

Traders may monitor GKOS for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

The filing date may lag the actual sale; traders should avoid over-weighting the disclosure versus the execution date and consider whether there are concurrent insider buys/sales or upcoming company-specific events.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-16.

Background

This is an SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by an officer, including execution details and confirmation of a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS chief development officer Navratil Tomas sold 1,537 shares for about $200,855 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted and short-lived.

Evidence & confidence

The transaction is an open-market sale by an officer and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild caution signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • GLAUKOS Corp

    Subject of the Form 4 insider transaction disclosure (GKOS).

  • Navratil Tomas

    Chief Development Officer who sold 1,537 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.